Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 173Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 154Lymphoma, Large B-Cell, Diffuse 134Lymphoma, Follicular 131Lymphoma, Mantle-Cell 93Leukemia 68Lymphoma, B-Cell, Marginal Zone 67Waldenstrom Macroglobulinemia 49Burkitt Lymphoma 43Lymphoma, B-Cell 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Hodgkin Disease 36Recurrence 24Lymphoma, Large-Cell, Immunoblastic 24Neoplasms 15Myelodysplastic Syndromes 15Lymphoma, Large-Cell, Anaplastic 15Multiple Myeloma 13Leukemia, Myeloid, Acute 12Lymphoma, T-Cell, Cutaneous 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Hematologic Neoplasms 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Immunoblastic Lymphadenopathy 8Sezary Syndrome 7Mycosis Fungoides 7Lymphoma, T-Cell 7

Interventions

Mycophenolic Acid 3Cyclosporine 3midostaurin 2fludarabine phosphate 2Whole-Body Irradiation 2Therapeutics 2Peripheral Blood Stem Cell Transplantation 2Darbepoetin alfa 2thymoglobulin 1ibrutinib 1hydrocortisone valerate 1ferrous sulfate 1ferric gluconate 1avapritinib 1Sunitinib 1Sucrose 1Rituximab 1Oxycodone 1Morphine 1Methylprednisolone Hemisuccinate 1Methylprednisolone Acetate 1Methylprednisolone 1Methadone 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Granisetron 1Filgrastim 1Epoetin Alfa 1Enzyme-Linked Immunosorbent Assay 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Mast-Cell × Rituximab × Clear all
NCT00186628 2017-11-28

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

Stanford University

Phase 2 Completed
36 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Mast-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡